Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

By sjmartinez • December 24, 2022

Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. PMID: 36561085; PMCID: PMC9733124.

Tags: Cardiology/Epi, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, Publications, sodium-glucose cotransporter-2 inhibitor

Optimization of Image Quality for Quantitative Multicontrast Atherosclerosis Characterization (qMATCH): Comparison between Transverse and Coronal Acquisitions

Hsu YC, Lu M, Llanes A, Keushkerian MJ, Nguyen KL, Johnson K, Altbach MI, Morris HD, DeMarco JK, Deshpande V, Mitsouras D, Saloner D, McNally[...]

Serial Assessment of Patient-Reported Health Status and Subsequent Clinical Outcomes in Atrial Fibrillation

Shiraishi Y, Nakamaru R, Kohsaka S, Sandhu AT, Heidenreich PA, Ikemura N, Sawano M, Niimi N, Kimura T, Katsumata Y, Nishiyama T, Ueda I, Takatsuki[...]

Electrically functionalized body surface for deep-tissue bioelectrical recording

Zhang D, Zhao G, Zhang Y, Xu D, Wang S, Wang K, Zhou B, Ling Y, Liu Y, Cui Q, Yin J, Zhu E, Zhao[...]